Crucell Announces Product Approval in Korea for Quinvaxem Vaccine
Quinvaxem(TM) combines antigens for protection against five important childhood diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B and Haemophilus influenzae type b, one of the leading causes of bacterial meningitis in children. According to Crucell, it is the first internationally available fully liquid vaccine containing all five of the above antigens to reach the market, offering a major advantage in terms of convenience of use. Supranational organizations are major customers for combination vaccines, which are used in mass vaccination programs in developing countries.
Crucell will start production of the Quinvaxem(TM) vaccine immediately at its Korean subsidiary. First sales are expected in the second half of 2006. The current demand exceeds 50 million doses, with the annual demand expected to increase to more than 150 million doses per year over the next five years.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.